COVID-19与重症哮喘生物制剂:比利时重症哮喘登记数据
该研究基于比利时重症哮喘登记队列,发现重症哮喘患者中COVID-19病例数少,无死亡或极重症病程;使用生物制剂治疗重症过敏性哮喘或重症嗜酸性哮喘与COVID-19风险升高无关。
要点
- 重症哮喘患者中COVID-19病例少,无死亡或极重症。
- 生物制剂使用未增加COVID-19风险。
- 抗IL-5/IL-5R导致的嗜酸性粒细胞减少未明确增加风险。
核心结论
- 重症哮喘患者使用生物制剂与COVID-19风险升高无关。
研究设计与样本
- 基于比利时重症哮喘登记队列的重症哮喘患者分析。
主要发现
- 队列中发现少量COVID-19病例,无死亡或极重症病程。
临床怎么用
- 重症哮喘患者可继续使用生物制剂,无需因COVID-19风险而停药。
局限性
- COVID-19病例数少,可能限制统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In a cohort of severe asthma patients, a small number of COVID-19 cases was found; none resulted in death or a very severe disease course. Use of biologics for severe allergic or severe eosinophilic asthma was not associated with a higher risk of COVID-19. https://bit.ly/3ndZmyD Epidemiological studies suggest that patients with asthma are not at an increased risk of severe coronavirus disease 2019 (COVID-19) caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1–3]. Recent studies indicate that the severity of COVID-19 in patients with asthma is likely to depend on multiple factors. A type 2-low asthma phenotype, use of oral corticosteroids and severe asthma could be aggravating factors, while maintenance treatment with inhaled corticosteroids (ICS) and good asthma control are probably protective [4]. However, there is currently scarce information on the risk associated with COVID-19 in subjects with severe asthma and/or the use of biologics. Since eosinopenia is a biomarker for the severity of COVID-19 [5], the eosinophil depletion induced by anti-IL5 and anti-IL5 receptor blocking monoclonal antibodies raises concern in patients and their treating physicians.
引用
- Hanon S, Brusselle G, Deschampheleire M, et al. COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry. Eur Respir J. 2020. PMID: 33093115. doi:10.1183/13993003.02857-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。